| Abstract |
: |
Aims: The main aim of the study is to compare the efficacy of newer antifungals like Luliconazole, Amorolfine, eberconazole, sertaconazole and terbinafine cutaneous mycoses (commonest presentation- tinea corporis). The study also aims to evaluate the effectiveness and safety of these newer topical antifungals. Study Design: Prospective parallel study and is a randomized, open-label, comparative study to evaluate the efficacy of newer antifungal drugs. Study population as a total 150 patients, needed to be enrolled in the study based on the inclusion and exclusion criteria. All the patients are aged between 18 to 80 years. Patients will receive the newer antifungals randomly and the test product needed be applied once daily for 1 week in patients with Tinea cruris/ Tinea corporis and for 2 weeks in patients with Tinea pedis. Follow up as the first follow up will be at 1 week and all the patients will be evaluated for clinical parameters and global clinical response. The second follow up is at 4 weeks and all the patients are again needed to the assessed for the parameters. Adverse events were recorded at each visit. Place and Duration of Study: Omni Hospitals, Kothapet, Hyderabad approvals , 4 weeks. Conclusions in this study, the efficacy was higher in Sertaconazole (93.3%) group followed by Luliconazole, Amorolfine, Terbinafine and Eberconazole(86.6%, 83.3%, 80.0% and 73.3% respectively). And the Adverse events order as follows Eberconazole>Luliconazole>Terbinafine>Amorolfine>Sertaconazole. |
Copyright to ENGG Journals Publications
